Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population

Neuroscience and Behavioral Physiology

Volumn 37, Issue 7, 2007, Pages 643-650

  Alfimova, M V ^a,b,c   Golimbet, V E ^a,b,c   Gritsenko, I K ^a,b,c   Lezheiko, T V ^a,b,c   Abramova, L I ^a,b,c   Strel'tsova, M A ^a,b,c   Khlopina, I V ^a,b,c   Ebstein, R ^a,b,c  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^b Specialist Clinical Hospital No 1   (Russian Federation)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cognitive functions; Dopamine; Gene polymorphism; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE 4 RECEPTOR; METHIONINE; VALINE;

ADULT; ARTICLE; ASSOCIATIVE MEMORY; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; FEMALE; GENETIC ANALYSIS; GENETIC LINKAGE; GENOTYPE; HUMAN; LINKAGE ANALYSIS; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SHORT TERM MEMORY; SPEECH INTELLIGIBILITY; VERBAL MEMORY; WORKING MEMORY;

ADULT; ALLELES; CATECHOL O-METHYLTRANSFERASE; COGNITION; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENE FREQUENCY; HUMANS; MALE; MEMORY, SHORT-TERM; METHIONINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PROBLEM SOLVING; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; VALINE; VERBAL BEHAVIOR;

EID: 34548385392     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-007-0064-x     Document Type: Article

References (49)

1. A. S. Avedisova and N. N. Verigo, "Cognitive deficit in schizophrenia," Ros. Psikhiat. Zh., 3, 21-24 (2002).
2. M. V. Alfimova and V. I. Trubnikov, "Inter-individual differences in the characteristics of cognitive activity in patients with and subjects at high risk of schizophrenia," Sots. Klin. Psikhiat., 9, No. 2, 5-13 (1999).
3. V. E. Golimbet, M. V. Alfimova, N. F. Mityushina, et al., "Association of the T102C locus of the 5HTR2A gene with attention and memory functions in patients with schizophrenia," Med. Genet., 3, No. 7, 340-344 (2004).
4. S. O. Kabanov and S. N. Mosolov, "Neuroleptics and neurocognitive deficit in schizophrenia," Ros. Psikhiat. Zh., 5, 60-68 (2003).
5. V. P. Kritskaya, T. K. Meleshko, and Yu. F. Polyakov, Pathology of Mental Activity in Schizophrenia: Motivation, Association, and Knowledge [in Russian], Moscow State University Press, Moscow (1991).
6. M. V. Magomedova, "Neurocognitive deficit and its relationship with the level of social competence in patients with schizophrenia," Sots. Klin. Psikhiat., 1, 92-98 (2000).
7. S. N. Mosolov, Scales for the Psychometric Assessment of the Symptoms of Schizophrenia and the Concepts of Positive and Negative Disturbances [in Russian], Moscow (2001).
8. S. N. Molosov and S. O. Kabanov, "Effects of prolonged treatment with quetiapine in patients with paranoid schizophrenia," Zh. Nevrol. Psikhiat., 104, No. 6, 27-34 (2004).
9. M. Akil, B. S. Kolachana, D. A. Rothmond, et al., "Catechol-O-methyl-transferase genotype and dopamine regulation in the human brain. J. Neurosci., 2003; 23, 2008-2013 (2003).
10. C. E. Bearden, A. F. Jawad, D. R. Lynch, et al., "Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22qll.2 deletion syndrome," Amer. J. Psychiat., 161, 1700-1702 (2004).
11. M. A. Bellgrove, Z. Hawi, N. Lowe, et al., "DRD4 gene variants and sustained attention in attention deficit hyperactivity disorder (ADHD): Effects of associated alleles at the VNTR and-521 SNP," Amer. J. Med. Genet. B. Neuropsychiatr. Genet., 136, 81-86 (2005).
12. A. Bertolino, G. Caforio, G. Blasi, et al., "Interaction of COMT [Val(108/ 158)Met] genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia," Amer. J. Psychiat., 161, 1798-1805 (2004).
13. R. M. Bilder, J. Volavka, P. Czobor, et al., "Neurocognitive correlates of the COMT (Val158Met)polymorphism in chronic schizophrenia," Biol. Psychiat., 52, 701-707 (2002).
14. R. M. Bilder, J. Volavka, H. M. Lachman, and A. A. Grace, "The catechol-O-methyltransferase polymorphism: Relations to the tonicphasic dopamine hypothesis and neuropsychiatric phenotypes," Neuropsychopharmacology 29, 1943-1961 (2004).
15. R. W. Buchanan, M. Davis, D. Goff, et al., "A summary of the FDANIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia," Schizophr. Bull., 31, 5-19 (2005).
16. C. M. De Frias, K. Annerbrink, L. Westberg, et al., "COMT gene polymorphism is associated with declarative memory in adulthood and old age," Behav. Genet., 34, 533-539 (2004).
17. D. De Quervain, K. Henke, A. Aerni, et al., "A functional genetic variation of 5-HT2a receptor affects human memory," Nat. Neurosci., 6, 1141-1142 (2003).
18. A. Diamond, L. Briand, J. Fossella, and L. Gehlbach, "Genetic and neurochemical modulation of prefrontal cognitive functions in children," Amer. J. Psychiatr., 161, 125-132 (2004).
19. G. Dreisbach, J. Muller, T. Goschke, et al., "Dopamine and cognitive control: The influence of spontaneous eyeblink rate and dopamine gene polymorphisms on perseveration and distractibility," Behav. Neurosci., 119, 483-490 (2005).
20. M. F. Egan, T. E. Goldberg, B. S. Kolachana, et al., "Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia," Proc. Natl. Acad. Sci. USA, 98, 6917-6922 (2001).
21. G. Emilien, J. M. Maloteaux, M. Geurts, and M. J. Owen, "Dopamine receptors and schizophrenia: Contribution of molecular genetics and clinical neuropsychology," Int. J. Neuropsychopharmacol., 2, 197-227 (1999).
22. J. Fossella, T. Sommer, J. Fan, et al., "Assessing the molecular genetics of attention networks," BMC Neurosci., 3, 14-21 (2002).
23. S. J. Glatt, S. V. Faraone, and M. T. Tsuang, "Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: Meta-analysis of case-control and family-based studies," Amer. J. Psychiatr., 160, 469-476 (2003).
24. T. E. Goldberg, M. F. Egan, T. Gscheidle, et al., "Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia," Arch. Gen. Psychiatr., 60, 889-896 (2003).
25. P. S. Goldman-Rakic and L. D. Selemon, "Frontal and anatomical aspects of prefrontal pathology in schizophrenia," Schizophr. Bull., 23, 437-458 (1997).
26. I. I. Gottesman and T. D. Gould, "The endophenotype concept in psychiatry: Etymology and strategic intentions," Amer. J. Psychiatr., 160, 1-10 (2003).
27. M. F. Green and K. H. Neuchterlein, "Should schizophrenia be treated as a neurocognitive disorder?" Schizophr. Bull., 25, 309-318 (1999).
28. B. C. Ho, T. H. Wassink, D. S. O'Leary, et al., "Catechol-O-methyltransferase Val158Met gene polymorphism in schizophrenia: Working memory, frontal lobe MRI morphology and frontal cerebral blood flow," Mol. Psychiatr., 10, 287-298 (2005).
29. E. J. Jonsson, C. S. Goran, M. M. Nothen, and S. Cichon, "Dopamine receptor gene (DRD4) variants and schizophrenia: Meta-analyses," Schizophr. Res., 61, 111-119 (2003).
30. R. Joober, J. Gauthier, S. Lal, et al., "Catechol-O-methyltransferase Val108/158Met gene variants associated with performance on the Wisconsin Card Sorting Test," Arch. Gen. Psychiatr., 59, 662-663 (2002).
31. W. S. Kremen, L. J. Seidman, J. P. Pepple, et al., "Neuropsychological risk indicators for schizophrenia: A review of family studies," Schizophr. Res., 20, 103-119 (1994).
32. H. Y. Lane, C. C. Lee, Y. C. Liu, and W. H. Chang, "Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics," Pharmacogenomics, 6, 139-149 (2005).
33. V. S. Mattay, T. E. Goldberg, F. Fera, et al., "Catechol-O-methyltransferase Val158Met genotype and individual variation in the brain response to amphetamine," Proc. Natl. Acad. Sci. USA, 100, 6186-6191 (2003).
34. A. K. Malhotra, L. J. Kestler, C. Mazzanti, et al., "Functional polymorphism in the COMT gene and performance on a test of prefrontal cognition," Amer. J. Psychiatr., 159, 652-654 (2002).
35. J. H. Meador-Woodruff, V. Haroutunian, P. Powchik, et al., "Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia," Arch. Gen. Psychiatr., 54, 1089-1095 (1997).
36. Y. Okuyama, H. Ishiguro, M. Toru, and T. Arinami, "A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia," Biochem. Biophys. Res. Commun., 258, 292-295 (1999).
37. M. A. Palmatier, A. M. Kang, and K. K. Kidd, "Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles," Biol. Psychiatr., 46, 557-567 (1999).
38. A. Rosa, V. Peralta, M. J. Cuesta, et al., "New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis," Amer. J. Psychiatr., 161, 1110-1112 (2004).
39. D. J. Sanger, "The search for novel antipsychotics: Pharmacological and molecular targets," Expert. Opin. Ther. Targets, 8, 531-641 (2004).
40. L. A. Schmidt, N. A. Fox, K. Perez-Edgar, et al., "Association of DRD4 with attention problems in normal childhood development," Psychiatr. Genet., 11, 25-29 (2001).
41. A. Serretti, F. Macciardi, M. Catalano, et al., "Genetic variants of dopamine receptor D4 and psychopathology," Schizophr. Bull., 25, 609-618 (1999).
42. N. C. Stefanis, J. Van Os, D. Avramopoulos, et al., "Variation in catechol-O-methyltransferase Val158Met genotype associated with schizotypy but not cognition: A population study in 543 young men," Biol. Psychiatr., 56, 510-515 (2004).
43. E. Taerk, N. Grizenko, L. Ben Amor, et al., "Catechol-O-methyltransferase (COMT) Val108/158Met polymorphism does not modulate executive function in children with ADHD," BMC Mol. Genet., 5, 30 (2004).
44. T. Toulopoulou and R. M. Murray, "Verbal memory deficit in patients with schizophrenia: An important future target for treatment," Expert Rev. Neurother., 4, 43-52 (2004).
45. S. J. Tsai, Y. W. Chen, et al., "Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females," Neurosci. Lett., 338, 123-126 (2003).
46. X. Wang, P. Zong, and Z. Yan, "Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex," J. Neurosci., 22, 9185-9193 (2002).
47. T. W. Weickert, T. E. Goldberg, A. Mishara, et al., "Catechol-O-methyltransferase Val108/l58Met genotype predicts working memory response to antipsychotic medications," Biol. Psychiatr., 56, 677-682 (2004).
48. D. R. Weinberger, M. F. Egan, A. Bertolino, et al., "Prefrontal neurons and the genetics of schizophrenia," Biol. Psychiatr., 50, 825-844 (2001).
49. K. Zhang, C. J. Grady, E. M. Tsapakis, et al., "Regulation of working memory by dopamine D4 receptor in rats," Neuropsychopharmacol., 29, 1648-1655 (2004).